Pancreatic Cancer Research

ResearcherWakayama Medical UniversityActive in the last 2 years

Takashi Tamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5611-2509; OpenAlex author ID A5044152976. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 4 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 18

  1. Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S-1, Irinotecan, and Oxaliplatin as Second-Line Chemotherapy After Gemcitabine Plus Nab… Co-author DOI 10.1002/jhbp.70122↗
  2. Reply to "Prognostic value of functional assessment in sarcopenia among pancreatic cancer patients". Co-author DOI 10.1007/s00535-026-02446-w↗
  3. Contrast-enhanced harmonic endoscopic ultrasonography (EUS)-guided tissue acquisition significantly improves diagnostic yield for small liver metastases derive… Co-author DOI 10.1016/j.pan.2025.12.001↗
  4. Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage. Co-author DOI 10.1111/den.70229↗
  5. Impact of sarcopenia and changes in skeletal muscle mass on prognosis of patients with pancreatic ductal adenocarcinoma receiving chemotherapy with first-line … Co-author DOI 10.1007/s00535-025-02283-3↗
  6. K-ras gene mutation analysis to diagnosis pancreatic adenocarcinoma from endoscopic ultrasound-guided tissue acquisition; a systematic review and meta-analysis. Co-author DOI 10.1016/j.pan.2023.11.012↗
  7. Gastrojejunostomy versus endoscopic duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer: a propensity score… Co-author DOI 10.1007/s00464-022-09685-x↗
  8. Utility of contrast-enhanced harmonic endoscopic ultrasonography for prediction of pathological response after neoadjuvant chemotherapy in patients with pancre… Co-author DOI 10.1016/j.pan.2023.10.016↗
  9. Fully covered metal stents vs plastic stents for preoperative biliary drainage in patients with resectable pancreatic cancer without neoadjuvant chemotherapy: … Co-author DOI 10.1002/jhbp.1090↗
  10. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gem… Co-author DOI 10.1016/j.pan.2021.12.013↗
  11. Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cance… Co-author DOI 10.1016/j.pan.2022.04.005↗
  12. Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers14030551↗
  13. Computed tomography findings for predicting the future occurrence of pancreatic cancer: value of pancreatic volumetry. Co-author DOI 10.1007/s10147-021-01915-x↗
  14. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  15. Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: A prospective study. Co-author DOI 10.1111/jgh.15661↗
  16. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… Co-author DOI 10.1097/md.0000000000018718↗
  17. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Early Diagnosis of Small Pancreatic Cancer. Co-author DOI 10.3390/diagnostics10010023↗
  18. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. Co-author DOI 10.1007/s00535-018-1519-2↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Kitano · 17 shared papers, 2019–2026 · strength 2.94
  2. Masahiro Itonaga · 14 shared papers, 2019–2026 · strength 2.31
  3. Yasunobu Yamashita · 14 shared papers, 2019–2026 · strength 2.31
  4. Reiko Ashida · 12 shared papers, 2021–2026 · strength 2.29
  5. Yuki Kawaji · 13 shared papers, 2020–2026 · strength 2.20
  6. Tomoya Emori · 10 shared papers, 2021–2026 · strength 1.76
  7. Keiichi Hatamaru · 10 shared papers, 2019–2023 · strength 1.21
  8. Manabu Kawai · 9 shared papers, 2020–2023 · strength 1.09
  9. Hiroki Yamaue · 4 shared papers, 2020–2022 · strength 0.42
  10. Yuji Kitahata · 3 shared papers, 2020–2023 · strength 0.36
  11. Mamoru Takenaka · 2 shared papers, 2023–2026 · strength 0.35
  12. Takeshi Ogura · 2 shared papers, 2023–2026 · strength 0.35
  13. Ippei Matsumoto · 2 shared papers, 2023–2026 · strength 0.35
  14. Ken‐ichi Okada · 3 shared papers, 2020–2021 · strength 0.30
  15. Seiko Hirono · 3 shared papers, 2020–2021 · strength 0.30
  16. Motoki Miyazawa · 2 shared papers, 2020–2021 · strength 0.21
  17. Akiko Tsujimoto · 1 shared paper, 2026 · strength 0.20
  18. Koh Kitagawa · 1 shared paper, 2026 · strength 0.20
  19. Yuki Ishikawa‐Kakiya · 1 shared paper, 2026 · strength 0.20
  20. Tsukasa Ikeura · 1 shared paper, 2026 · strength 0.20
  21. Yoshihiro Nishikawa · 1 shared paper, 2026 · strength 0.20
  22. Tomoaki Matsumori · 1 shared paper, 2026 · strength 0.20
  23. Atsuhiro Masuda · 1 shared paper, 2026 · strength 0.20
  24. Takashi Ito · 1 shared paper, 2026 · strength 0.20
  25. Toshifumi Doi · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.